ISAL 2023 | Targeting leukemic stem cells in AML
Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, provides insights into the role of leukemic stem cells (LSCs) in acute myeloid leukemia (AML), outlining the challenges associated with targeting LSCs, and highlighting how targeting LSC cell surface proteins, metabolism, and cell cycle may help eradicate LSCs. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
R.M. is on the Advisory Boards of Kodikaz Therapeutic Solutions, TenSixteen Bio, Roche, Cullgen, and 858 Therapeutics and is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences. R.M. receives research support from Gilead Sciences. R.M. is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics.
